The Infusion Edge
Download PDF (2.4 MB)The Infusion Edge is your quarterly inside track to the future of our industry, delivering actionable market intelligence and reimbursement policy updates. Each issue highlights member and partner achievements, exclusive partner-driven insights, and new opportunities to grow and lead the way forward—together.
A Message from Leadership
Highlights from the inaugural IIS Town Hall
Thank you to everyone who joined us for our first IIS Town Hall on March 27th featuring our strategic partner, IPA (Infusion Providers Alliance). It was a valuable opportunity to connect members across our network for an open and timely conversation around the challenges, opportunities, and changes shaping the infusion industry today.
Missed our first Town Hall? No problem! Click here to view the meeting in its entirety and review the session Q&A.
The discussion outlined how upcoming Medicare drug price negotiation changes under the Inflation Reduction Act—particularly replacing ASP with lower “maximum fair prices”—could significantly reduce reimbursement for infused therapies, putting financial pressure on independent practices and potentially limiting patient access to care in community settings. IPA leaders also discussed likely spillover effects on commercial contracts and site-of-care shifts, while highlighting HR 4299 as a key legislative solution to protect provider reimbursement and maintain patient access.
This Town Hall reflected IIS’s ongoing commitment to delivering added value by creating meaningful opportunities to engage directly with trusted strategic partners. Through these conversations, members gain access to deeper industry insight, advocacy support, reimbursement expertise, and operational resources designed to help infusion providers navigate change with confidence.
Take Action for Advocacy: If you would like to follow up with IPA on contacting your elected officials regarding HR 4299, click the button below to reach out to Elliott Warren.
When's the next Town Hall?
We’re excited to continue supporting our members through a second IIS Town Hall this fall. To ensure we address the topics that matter most to you, click here to vote on the focus for our next session. Additional details will be shared soon, and we look forward to connecting again.
Tamra Townsend, CEO | Katie Ivy, COO
Built on trust. Focused on patients. Leading the way forward.
A look at what’s ahead
Summer interns: We are excited to welcome two new summer interns to the IIS family this season! Please join us in welcoming Carissa Twiss, a 2026 graduate from the University of North Texas in Denton with a Bachelor of Business Administration in Marketing, and Anna Hockett, a 2026 graduate from the University of Texas at Dallas with a Bachelor of Science in Marketing. We are thrilled to have them on board and look forward to a great summer.
Coming soon: Be on the lookout for the launch of CompassIQ™, our proprietary member access portal, launching in the 1st half of 2026. It will empower members to track:
- Purchasing history and member benefits
- Contract status and current pricing
- Incentive programs and rebates
Upcoming conferences: Look for IIS at these events.
- The Consortium of MS Centers Annual Meeting: 5/27 – 5/30 | Charlotte, NC | Booth #844
- NICA: 7/9 – 7/10 | Las Vegas, NV | Booth #236
- TNS Summer Conference:7/31-8/1 | San Antonio, TX
- AANEM: 9/29 – 10/2 | Orlando, FL | Booth #905
Save the Date
IIS Partner Appreciation Reception
Our 5th Annual IIS Partner Appreciation Reception, "Defying the Odds. Defining the Future." will be celebrated on 7/9 at 6:30 pm in Las Vegas.
Check your inbox for a formal invitation from announcements@infinityinfusion.com.
Follow us on LinkedIn for the latest updates
Compliance Corner with IPA
Federal Drug Pricing Reform: What Providers Should Know
The Trump Administration has inked deals with 17 major pharmaceutical manufacturers, impacting pricing to the Medicaid program, future product launches as well as domestic investments and avoidance of tariffs. The agreements are confidential but reportedly last for three years. The administration continues to push congress to “codify” most favored nation pricing. In March, Representative Dan Meuser (R-PA-9) introduced MFN legislation.
Meanwhile, the Centers for Medicare & Medicaid Services Center for Medicare and Medicaid Innovation (CMMI) proposed two drug pricing models imposing rebates to reflect lower, international pricing benchmarks. The Global Benchmark for Efficient Drug Pricing (GLOBE) will test these international reference pricing in Part B and the Guarding U.S. Medicare Against Rising Drug Costs (GUARD) will test international reference drug pricing benchmarks in Part D. The models reflect a similar use of international reference pricing concepts as those included in the prior Most Favored Nation (MFN) drug pricing model, by applying those international benchmarks to rebate calculations.
Partner Perspective with NICA
Staying Ahead of Industry Change
Through IIS’s strategic partnership with National Infusion Center Association, members remain connected to the legislative and regulatory developments shaping the future of infusion care nationwide.
As rising healthcare costs and evolving reimbursement models continue to impact providers and patients alike, NICA remains at the forefront of advocacy efforts designed to protect patient access and support the sustainability of community-based infusion providers.
Key areas of focus include:
- Medicare Drug Price Negotiation Program (MDPNP): NICA continues advocating for provider protections as CMS moves forward with negotiated pricing for Part B drugs. Concerns remain regarding reimbursement reductions tied to negotiated pricing and the potential impact on patient access and provider sustainability.
- PBM Reform & Drug Pricing Transparency: Recent federal legislation and increased scrutiny surrounding PBM practices continue reshaping the reimbursement landscape. NICA has actively supported efforts aimed at increasing transparency, limiting spread pricing, and protecting patient affordability.
- Most Favored Nation (MFN) Pricing: NICA continues engaging with policymakers regarding MFN pricing proposals and CMS’s proposed GLOBE model, emphasizing the potential impact these policies may have on treatment access and provider viability.
Together, these developments reinforce the growing importance of active advocacy across the infusion industry. IIS remains committed to connecting members with trusted partners like NICA to provide timely insights, advocacy resources, and meaningful representation in an evolving healthcare environment.
Questions or topics you’d like to learn more about in future newsletters? Contact us at: announcements@infinityinfusion.com.
Member Provider Spotlight
Palmetto
Since its founding in 1999, Palmetto Infusion has established a reputation for providing excellent care and services to both home infusion and ambulatory clinic patients, providing safe, convenient, and affordable treatment options for patients living with chronic and acute diseases.
With a well-established home infusion business and more than 50 ambulatory infusion clinics across the Carolinas, Georgia, Alabama, Florida, and Virginia, Palmetto Infusion is the trusted provider of infusion services in the Southeast.
IIS has been a great partner over the last 9 years. The ASP pricing model has allowed us to increase our IVIG volume, ensure reliable reimbursement, and support further growth. All of this allows us to provide the Palmetto Experience to more patients in need.
“Our partnership with IIS over the past nine years has been instrumental in supporting our growth. Their ASP-based pricing model has enabled increased IVIG access, more predictable reimbursement, and the ability to expand care to more patients. IIS has also been a strong advocate for the AIC model—consistently negotiating on our behalf and providing the stability and reliability needed to deliver the Palmetto Experience.”
Product & Partner Spotlight
2026 DCLF Conference Brief
By Julia Hancock, IIS VP of Trade & Commercial Growth
At the 2026 Drug Channels Leadership Forum (DCLF), leaders from across the pharmaceutical ecosystem—including manufacturers, providers, payers, and innovators—came together to discuss the forces reshaping healthcare and the future of the drug channel.
Key themes discussed included:
- 340B program scrutiny and reimbursement pressures
- CMS pricing reform and evolving PBM regulation
- Vertical integration across healthcare organizations
- Growing demand for transparent, patient-centered pricing models
One message remained consistent throughout the conference: the healthcare landscape is changing rapidly, and success increasingly depends on understanding how every part of the drug channel connects.
For manufacturers and providers alike, staying informed, adaptable, and strategically aligned will be critical as reimbursement models, access strategies, and patient affordability continue to evolve.
Click below to read the full conference brief.
May 6–12
IIS celebrates National Nurses Week
In May, IIS proudly celebrated National Nurses Week and recognized five nurses across our network who make exceptional patient care possible. Because behind every treatment is a patient—and behind every patient experience is a nurse showing up with compassion, expertise, and dedication.
Throughout the week, we highlighted nurses and shared their perspectives, experiences, and commitment to caring for patients day in and day out. Their work extends far beyond clinical care, offering reassurance, advocacy, education, and support to patients navigating complex conditions.
Read more about some of the wonderful nurses making a difference across the IIS network.
“I am a nurse so that I can help others have a better quality of life. Being a part of helping them get better and to see that improvement gives me satisfaction that what I do makes a difference.”